Anti-obesity drugs: Fighting fat

  title={Anti-obesity drugs: Fighting fat},
  author={Peter Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
  • P. Kirkpatrick
  • Published 1 August 2006
  • Biology
  • Nature Reviews Drug Discovery
Rising levels of obesity and associated health problems in many countries worldwide have led to a burgeoning interest in drugs that could promote weight loss. Writing in the British Journal of Pharmacology, Pauwels and colleagues now provide evidence that a novel 5-hydroxytryptamine (5-HT)6 receptor partial agonist — known as E-6837 — could represent a novel approach for the management of obesity. Several previous investigations have indicated that the 5-HT6 receptor, which is distributed… 



Chronic 5‐HT6 receptor modulation by E‐6837 induces hypophagia and sustained weight loss in diet‐induced obese rats

Results show that the 5‐HT6 receptor partial agonist, E‐6837, is a promising new approach to the management of obesity with the potential to produce greater sustained weight loss than sibutramine.

Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.

Novel series of indolyl sulfonamides have been designed and prepared as selective and high-affinity serotonin 5-HT(6) receptor ligands, which should allow for the detailed study of the role of the 5- HT( 6) receptor in relevant animal models of disorders such as cognition deficits, depression, anxiety, or obesity.